{"DataElement":{"publicId":"12943960","version":"1","preferredName":"Prostate Carcinoma Digital Rectal Examination T Category","preferredDefinition":"Based on digital rectal examination, the extent of the primary prostate carcinoma based on information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter).","longName":"PC_DRE_T_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"12939966","version":"1","preferredName":"Prostate Carcinoma Digital Rectal Examination T Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._An examination that checks for abnormalities of organs or other structures in the pelvis and lower abdomen. During a digital rectal exam, a health professional inserts a lubricated, gloved finger of one hand into the rectum and may use the other hand to press on the lower abdomen or pelvic area.:One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"12939965v1.00:2442923v1.00","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"12939965","version":"1","preferredName":"Prostate Carcinoma Digital Rectal Examination","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._An examination that checks for abnormalities of organs or other structures in the pelvis and lower abdomen. During a digital rectal exam, a health professional inserts a lubricated, gloved finger of one hand into the rectum and may use the other hand to press on the lower abdomen or pelvic area.","longName":"C4863:C17631","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Digital Rectal Examination","conceptCode":"C17631","definition":"An examination that checks for abnormalities of organs or other structures in the pelvis and lower abdomen. During a digital rectal exam, a health professional inserts a lubricated, gloved finger of one hand into the rectum and may use the other hand to press on the lower abdomen or pelvic area.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CF8E94-9AEA-52F0-E053-731AD00A4FB7","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2442923","version":"1","preferredName":"T Stage","preferredDefinition":"One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"C25728","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-57CF-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-01-10","modifiedBy":"ONEDATA","dateModified":"2006-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CF8E94-9AEF-52F0-E053-731AD00A4FB7","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12939824","version":"1","preferredName":"Prostate Carcinoma Digital Rectal Examination T Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._An examination that checks for abnormalities of organs or other structures in the pelvis and lower abdomen. During a digital rectal exam, a health professional inserts a lubricated, gloved finger of one hand into the rectum and may use the other hand to press on the lower abdomen or pelvic area._One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._A grouping of items based on some commonality or by user defined characteristics.","longName":"PC_DRE_T_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No palpable lesion (<= cT1c)","valueDescription":null,"ValueMeaning":{"publicId":"12940065","version":"1","preferredName":"Less Than or Equal To Prostate Cancer cT1c TNM Finding v8","longName":"12940065v1.00","preferredDefinition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways._Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Less Than or Equal To","conceptCode":"C61586","definition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest is smaller than the other object in one of these ways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Cancer cT1c TNM Finding v8","conceptCode":"C140133","definition":"Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D01200-6750-6EEF-E053-731AD00A3E50","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D01200-6751-6EEF-E053-731AD00A3E50","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Palpable lesion (CT2)","valueDescription":null,"ValueMeaning":{"publicId":"6032097","version":"1","preferredName":"Prostate Cancer cT2 TNM Finding v8","longName":"6032097","preferredDefinition":"Prostate cancer in which the tumor is palpable and confined within the prostate. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer cT2 TNM Finding v8","conceptCode":"C140134","definition":"Prostate cancer in which the tumor is palpable and confined within the prostate. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E9222F5-C1F6-5936-E053-F662850A7DD3","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D01200-6752-6EEF-E053-731AD00A3E50","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Extraprostatic extension (cT3a)","valueDescription":null,"ValueMeaning":{"publicId":"6032087","version":"1","preferredName":"Prostate Cancer cT3a TNM Finding v8","longName":"6032087","preferredDefinition":"Prostate cancer with extraprostatic extension (unilateral or bilateral). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer cT3a TNM Finding v8","conceptCode":"C140141","definition":"Prostate cancer with extraprostatic extension (unilateral or bilateral). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E9222F5-C138-5936-E053-F662850A7DD3","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D01200-6753-6EEF-E053-731AD00A3E50","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Seminal vessicle invasion (CT3b)","valueDescription":null,"ValueMeaning":{"publicId":"6032085","version":"1","preferredName":"Prostate Cancer cT3b TNM Finding v8","longName":"6032085","preferredDefinition":"Prostate cancer in which the tumor invades seminal vesicle(s). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer cT3b TNM Finding v8","conceptCode":"C140142","definition":"Prostate cancer in which the tumor invades seminal vesicle(s). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E9222F5-C112-5936-E053-F662850A7DD3","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D01200-6754-6EEF-E053-731AD00A3E50","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Organ invasion (cT4)","valueDescription":null,"ValueMeaning":{"publicId":"6032083","version":"1","preferredName":"Prostate Cancer cT4 TNM Finding v8","longName":"6032083","preferredDefinition":"Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer cT4 TNM Finding v8","conceptCode":"C140143","definition":"Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E9222F5-C0EC-5936-E053-F662850A7DD3","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D01200-6755-6EEF-E053-731AD00A3E50","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12939823","version":"1","preferredName":"Prostate Carcinoma Digital Rectal Examination T Category Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._An examination that checks for abnormalities of organs or other structures in the pelvis and lower abdomen. During a digital rectal exam, a health professional inserts a lubricated, gloved finger of one hand into the rectum and may use the other hand to press on the lower abdomen or pelvic area._One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._A grouping of items based on some commonality or by user defined characteristics.","longName":"12939823v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Digital Rectal Examination","conceptCode":"C17631","definition":"An examination that checks for abnormalities of organs or other structures in the pelvis and lower abdomen. During a digital rectal exam, a health professional inserts a lubricated, gloved finger of one hand into the rectum and may use the other hand to press on the lower abdomen or pelvic area.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F62A-FB2F-64CE-E053-731AD00A01B0","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F62A-FB34-64CE-E053-731AD00A01B0","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"DRE","type":"Preferred Question Text","description":"DRE","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D1185E-4C41-0A5C-E053-731AD00ADA9F","latestVersionIndicator":"Yes","beginDate":"2023-03-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}